STING agonists, as single agent, as well as in combination with ICIs and cancer vaccine, showed enhanced T cell-mediated anti-tumor immunity, reduction in metastatic burden and eradication of ICI-resistant tumors in a pre-clinical model [104]. Here, STING1 is linked to neoplasm.